News
The Prescient (ASX:PTX) share price rocketed 10% higher today. Here’s why
Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news its cancer treatment drug, OmniCAR, has been…
News
Prescient Therapeutics (ASX:PTX) returns successful immunogenicity results
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially de-risked. In silico immunogenicity testing of the company’s OmniCAR key…
News
Prescient shares rip higher as immunogenicity testing results for OmniCAR ‘could not have been better’
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As it builds out its OmniCAR cancer treatment platform, clinical stage…
News
Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a sobering reminder of the dangers involved in cell therapy. Image: Getty Safety in mind as Prescient Therapeutics develops next-generation CAR-T platform
Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a…
News
Prescient Therapeutics reaches a major CAR-T manufacturing milestone
In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced that it has successfully completed the manufacturing and…
News
Prescient equips CAR-T cells with cancer-fighting binders in manufacturing milestone
Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced another crucial step forward in the development of its CAR-T cancer treatment solutions. The company confirmed…
News
Prescient Therapeutics (ASX:PTX) manufactures new range of binders for CAR-T cancer therapy
Prescient Therapeutics (PTX) has slipped on the ASX today despite announcing some key developments for its CAR-T cancer therapy programs. The oncology company said today…
News
Making CAR-T “Druggable”
The terrible news this week that Tmunity Therapeutics, a clinical stage biotherapeutics company, has halted the development of its lead CAR-T therapy following the deaths…
News
‘Box’ clever: Biotechs embrace new tax rules for patents
Australia’s medical community has welcomed a new ‘patent box’ tax regime designed to encourage further investment into local medical and biotech research and development. Under…
News
Budget review: Here’s what ASX biotech players thought of the ‘patent box’
The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were…